Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.52
SQNM's Cash to Debt is ranked higher than
52% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 108.89 vs. SQNM: 0.52 )
SQNM' s 10-Year Cash to Debt Range
Min: 0.52   Max: No Debt
Current: 0.52

Equity to Asset -0.32
SQNM's Equity to Asset is ranked lower than
53% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SQNM: -0.32 )
SQNM' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.87
Current: -0.32

-0.32
0.87
F-Score: 4
Z-Score: -9.81
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -60.59
SQNM's Operating margin (%) is ranked higher than
71% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -66.46 vs. SQNM: -60.59 )
SQNM' s 10-Year Operating margin (%) Range
Min: -11450   Max: -55.06
Current: -60.59

-11450
-55.06
Net-margin (%) -66.13
SQNM's Net-margin (%) is ranked higher than
70% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -53.69 vs. SQNM: -66.13 )
SQNM' s 10-Year Net-margin (%) Range
Min: -10900   Max: -53.61
Current: -66.13

-10900
-53.61
ROA (%) -74.23
SQNM's ROA (%) is ranked higher than
55% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -18.63 vs. SQNM: -74.23 )
SQNM' s 10-Year ROA (%) Range
Min: -134.79   Max: -17.57
Current: -74.23

-134.79
-17.57
ROC (Joel Greenblatt) (%) -370.61
SQNM's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 840 Companies
in the Global Biotechnology industry.

( Industry Median: -179.37 vs. SQNM: -370.61 )
SQNM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1096.39   Max: -256.41
Current: -370.61

-1096.39
-256.41
Revenue Growth (%) 28.80
SQNM's Revenue Growth (%) is ranked higher than
93% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. SQNM: 28.80 )
SQNM' s 10-Year Revenue Growth (%) Range
Min: -20.6   Max: 293.1
Current: 28.8

-20.6
293.1
EBITDA Growth (%) -23.50
SQNM's EBITDA Growth (%) is ranked higher than
62% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: -9.80 vs. SQNM: -23.50 )
SQNM' s 10-Year EBITDA Growth (%) Range
Min: -57.8   Max: 45.7
Current: -23.5

-57.8
45.7
EPS Growth (%) -18.10
SQNM's EPS Growth (%) is ranked higher than
71% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. SQNM: -18.10 )
SQNM' s 10-Year EPS Growth (%) Range
Min: -59.3   Max: 43.7
Current: -18.1

-59.3
43.7
» SQNM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SQNM Guru Trades in Q1 2013

Louis Moore Bacon 300,000 sh (+500%)
Chuck Royce 1,256,000 sh (+51.14%)
Steven Cohen 4,411,119 sh (-8.45%)
» More
Q2 2013

SQNM Guru Trades in Q2 2013

Steven Cohen 400,000 sh (unchged)
Chuck Royce 1,256,000 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen 4,051,119 sh (-8.16%)
» More
Q3 2013

SQNM Guru Trades in Q3 2013

Chuck Royce 676,000 sh (-46.18%)
Steven Cohen 2,100,000 sh (-48.16%)
» More
Q4 2013

SQNM Guru Trades in Q4 2013

Chuck Royce Sold Out
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SQNM



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Sequenom, Inc.

Gurus Hold Five-Year Lows in Biotech, Utilities
A rapid-research tool, the GuruFocus Five-Year Low Value Screen currently highlights three diverse U.S. companies on a five-year low, two of them held by billionaire investors, and two with high yields. Here are the company updates and trading highlights, as of June 30, 2013. Read more...

Ratios

vs
industry
vs
history
P/S 1.78
SQNM's P/S is ranked higher than
90% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. SQNM: 1.78 )
SQNM' s 10-Year P/S Range
Min: 0.99   Max: 29.2
Current: 1.78

0.99
29.2
EV-to-EBIT 0.10
SQNM's EV-to-EBIT is ranked higher than
98% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. SQNM: 0.10 )
SQNM' s 10-Year EV-to-EBIT Range
Min: 3.1   Max: 111.3
Current: 0.1

3.1
111.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.40
SQNM's Price/Median PS Value is ranked higher than
92% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SQNM: 0.40 )
SQNM' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 8.3
Current: 0.4

0.28
8.3
Earnings Yield (Greenblatt) 843.40
SQNM's Earnings Yield (Greenblatt) is ranked higher than
96% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SQNM: 843.40 )
SQNM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 1271.1
Current: 843.4

0.9
1271.1
Forward Rate of Return (Yacktman) -34.59
SQNM's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. SQNM: -34.59 )
SQNM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 28.9
Current: -34.59

3.1
28.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QNMA.Germany
Sequenom, Inc., was incorporated in 1994 under the laws of the State of Delaware. It is a life sciences company providing innovative genetic analysis solutions to improve healthcare through its two operating segments: Molecular Diagnostics and Genetic Analysis. Molecular Diagnostics, in which Sequenom Center for Molecular Medicine, LLC or Sequenom CMM performs molecular diagnostic testing services utilizing its laboratory-developed tests (LDTs), which currently is focused on noninvasive prenatal and women's health related diagnostics and ophthalmology-related diagnostics, and plans to develop or acquire additional diagnostic tests in those and other fields including autoimmunity, neurology and oncology. Genetic Analysis segment researches, develops and commercializes components and applications for its proprietary Mass ARRAY system, a nucleic acid analysis research-use only system that measures genetic target material and variations. Product sales, services and contract research revenues from its Genetic Analysis segment are mainly derived from sales of its MassARRAY systems, which are comprised of hardware, software applications, consumable chips and reagents, as well as the provision of contract research services, to clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions and government agencies. The Company faces competition from various companies developing and commercializing diagnostic assays, and from various companies researching and developing prenatal diagnostic technology, and from various companies offering nucleic acid analysis systems and services. Competitors and potential competitors include Ikonysis, Inc., Verinata Health, Inc. (a wholly owned subsidiary of Illumina, Inc.), Celula Inc., Kellbenx, Inc., Cellscape Corp., Fluidigm Corp., Ariosa Diagnostics, Inc., Natera, Beijing Genomics Institute, and others. In the United States, IVD tests may require either premarket approval, or PMA, or premarket notification, or 510(k) clearance, from the FDA prior to marketing in the United States. Regulation by governmental authorities in the United States and other countries will be a significant factor in the development, testing, production and marketing of diagnostic products, including tests that may be developed by it or its corporate partners, collaborators or licensees.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide